-
Advancing Early-Stage Breast Cancer Monitoring with ctDNA Structural Variant Detection
A recent study published in Clinical Cancer Research (Jan 9, 2025) highlights the potential of structural variant (SV)-based circulating tumor DNA (ctDNA) detection in early-stage breast cancer (EBC). Unlike traditional…
-
Phase 3 EMBER-3 Trial: Imlunestrant in Advanced Breast Cancer
A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced…
-
Three First-Line Strategies for EGFR-Mutant NSCLC: How to Choose the Right One?
Clinicians and researchers continue to seek targeted treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC), with an increasing number of clinical trials evaluating combination therapies. Two recent high-profile studies, the FLAURA-2 and MARIPOSA trials, have led to the FDA approval of new first-line treatment options for EGFR-mutant NSCLC in 2024.
-
Honoring Dr. Abdullah Tarik Aslan and His Research on Antibiotic-Associated Nephrotoxicity
Dr. Abdullah Tarik Aslan, alongside his colleagues, has led an important multinational, multicenter cohort study investigating the risk of acute kidney injury (AKI) in patients receiving piperacillin-tazobactam (TZP) with either vancomycin (VAN) or teicoplanin (TEI).
-
Unlocking the Potential of Antibody-Drug Conjugates in Pancreaticobiliary Cancers: Mechanisms and Key Selection Criteria
Mechanism of ADCs and Antigenic Targets ADCs function through a three-component system, comprising a monoclonal antibody (mAb) targeting a tumor-specific antigen, a cytotoxic payload, and a linker that facilitates payload…
-
Breaking New Ground in GEP-NET Treatment: Everolimus Plus Lanreotide Doubles Progression-Free Survival in STARTER-NET Trial
Presented by Dr. Susumu Hijioka at the ASCO Gastrointestinal Cancers Symposium, the STARTER-NET trial explores new frontiers in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are…
-
ASCO GI Highlights! A Breakthrough for Cadonilimab in Gastrointestinal Cancers
From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) was held in San Francisco, USA. At this prestigious event, Cadonilimab, the world’s first bispecific antibody developed in China, achieved multiple breakthroughs in the treatment of gastrointestinal cancers.Several research teams, including Professors Jing Huang and Wang Qu…
-
ASCO GI 2025 | CD47 Blockade Combination Therapy Shows Anti-Tumor Potential in Previously Treated HER2-Positive Gastric Cancer
The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. During the conference, numerous high-impact research findings were presented, including the ASPEN-06 study (Abstract #332), a global Phase II/III randomized trial evaluating the efficacy of evorpact (Evo) in combination with trastuzumab, ramucirumab, and paclitaxel (TRP) in patients…
Connecting Medical Expertise through Media